Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds [Yahoo! Finance]
Cadrenal Therapeutics, Inc. (CVKD)
Company Research
Source: Yahoo! Finance
developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 285,715 shares of common stock of the originally issued in July 2023 , having an exercise price of per share, at a reduced exercise price of per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective post-effective amendment no. 1 to registration statement on Form S-1 on Form S-3 (No. 333-273384). The offering is expected to close on or about November 4, 2024 , subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series A-1 warrants to purchase up to 285,7
Show less
Read more
Impact Snapshot
Event Time:
CVKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVKD alerts
High impacting Cadrenal Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CVKD
News
- Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook [Yahoo! Finance]Yahoo! Finance
- Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech OutlookPR Newswire
- CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESSPR Newswire
- Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its price target raised by analysts at HC Wainwright from $3.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATEPR Newswire
CVKD
Sec Filings
- 11/14/24 - Form S-3
- 11/14/24 - Form SC
- 11/14/24 - Form D
- CVKD's page on the SEC website